How oncRNA Technology Could Revolutionize Cancer Diagnostics
Exai Bio combines novel oncRNA technology with AI to develop next-generation liquid biopsy tests that will aid in the detection of cancer.
Read MorePosted by Chris Wolski | Sep 2, 2022 | Cancer, Molecular Diagnostics |
Exai Bio combines novel oncRNA technology with AI to develop next-generation liquid biopsy tests that will aid in the detection of cancer.
Read MorePosted by Andy Lundin | Aug 25, 2022 | Cardiovascular |
Researchers found that a novel blood test can be used to easily evaluate disease severity in patients with pulmonary arterial hypertension.
Read MorePosted by Andy Lundin | Aug 19, 2022 | Lung Cancer |
A new collaborative project has successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva.
Read MorePosted by Andy Lundin | Aug 15, 2022 | Company News, Lung Cancer |
ENHERTU is a specifically engineered HER2 directed antibody drug conjugate developed and commercialized by Daiichi Sankyo and AstraZeneca.
Read MorePosted by Chris Wolski | Aug 12, 2022 | Allergy & Autoimmune |
KSL Beutner Laboratories (Beutner) has launched an IIF serum blood test in the U.S. that positively identifies laminin 332.
Read More